Aspira Women's Health Files S-1

TL;DR

Aspira Women's Health filed an S-1, looks like they're raising cash.

AI Summary

Aspira Women's Health Inc. filed an S-1 registration statement on January 8, 2025, to register securities under the Securities Act of 1933. The company, formerly known as Vermillion, Inc., Ciphergen Biosystems Inc., and Abiotic Systems, is incorporated in Delaware and headquartered in Austin, Texas. The filing indicates a potential offering of securities, though specific dollar amounts and dates for the offering are not detailed in this excerpt.

Why It Matters

This S-1 filing signals Aspira Women's Health Inc.'s intent to raise capital through a public offering, which could impact its future growth and operations.

Risk Assessment

Risk Level: medium — S-1 filings often precede significant corporate actions like stock offerings, which carry inherent market risks.

Key Numbers

• 333-284182 — SEC File Number (Identifies this specific registration statement with the SEC.)
• 2835 — SIC Code (Indicates the company operates in the 'IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES' industry.)

Key Players & Entities

• Aspira Women's Health Inc. (company) — Registrant
• January 8, 2025 (date) — Filing Date
• Securities Act of 1933 (legal_document) — Governing Act
• Vermillion, Inc. (company) — Former Company Name
• Ciphergen Biosystems Inc (company) — Former Company Name
• Abiotic Systems (company) — Former Company Name
• Delaware (jurisdiction) — State of Incorporation
• Austin, Texas (location) — Principal Executive Offices
• Sandra Milligan (person) — Interim Chief Executive Officer

FAQ

From the Filing

0001493152-25-001451.txt : 20250108 0001493152-25-001451.hdr.sgml : 20250108 20250108173032 ACCESSION NUMBER: 0001493152-25-001451 CONFORMED SUBMISSION TYPE: S-1 PUBLIC DOCUMENT COUNT: 7 FILED AS OF DATE: 20250108 DATE AS OF CHANGE: 20250108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aspira Women's Health Inc. CENTRAL INDEX KEY: 0000926617 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 330595156 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: S-1 SEC ACT: 1933 Act SEC FILE NUMBER: 333-284182 FILM NUMBER: 25519439 BUSINESS ADDRESS: STREET 1: 12117 BEE CAVES ROAD BUILDING THREE STREET 2: SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78738 BUSINESS PHONE: 512-519-0400 MAIL ADDRESS: STREET 1: 12117 BEE CAVES ROAD BUILDING THREE STREET 2: SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78738 FORMER COMPANY: FORMER CONFORMED NAME: VERMILLION, INC. DATE OF NAME CHANGE: 20070824 FORMER COMPANY: FORMER CONFORMED NAME: CIPHERGEN BIOSYSTEMS INC DATE OF NAME CHANGE: 20000316 FORMER COMPANY: FORMER CONFORMED NAME: ABIOTIC SYSTEMS DATE OF NAME CHANGE: 19950407 S-1 1 forms-1.htm As filed with the Securities and Exchange Commission on January 8, 2025 Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ASPIRA WOMEN’S HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 2835 33-0595156 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 12117 Bee Caves Road, Building III, Suite 100 Austin, Texas 78738 (512) 519-0400 (Address, including zip code and telephone number, including area code of registrant’s principal executive offices) Sandra Milligan Interim Chief Executive Officer Aspira Women’s Health Inc. 12117 Bee Caves Road, Building III, Suite 100 Austin, Texas 78738 (512) 519-0400 (Name, address, including zip code, and telephone number, including area code, of agent for service) Copies to: Jeffrey J. Fessler, Esq. Nazia J. Khan, Esq. Sheppard, Mullin, Richter & Hampton LLP 30 Rockefeller Plaza New York, NY 10112-0015 Tel.: (212) 653-8700 Lawrence Metelitsa, Esq. Lucosky Brookman LLP 101 Wood Avenue South, 5th Floor Woodbridge, NJ 08830 Tel.: (732) 395-4400 Approximate date of commencement of proposed sale to the public: As soon as practicable after the date this registration statement becomes effective. If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box: ☒ If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐ If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐ If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large acceler